Elekta has gained CE mark certification for its artificial intelligence (AI)-powered, adaptive CT-Linear Accelerator (Linac), Elekta Evo. It’s now available for sale and marketing in Europe.
 
Evo provides both offline and online plan adaptation. It also features improvements in its image-guided radiation therapy (IGRT) treatments, according to the company.
 
Using Evo, clinicians can choose the most suitable radiation therapy technique for each cancer patient’s individual case or treatment session. Evo was first introduced at this year’s Annual Congress of the European Society for Radiotherapy and Oncology (ESTRO 2024).
 
“With Evo, we are emphasizing flexibility regarding how and when clinics want to implement adaptive radiation therapy (ART),” said Maurits Wolleswinkel, Elekta’s President Linac and Software Solutions. “Some may prefer to continue their high throughput IGRT service and use ART for select cases and adapt plans when needed, all in one machine. Evo’s range of techniques and the ability to adopt new treatments at a pace that suits a clinicians’ needs have shown positive responses from our clinical research partners.”
 
Clinicians need high-quality images to help visualize tumors and organs at risk to facilitate contouring. Elekta said Evo addresses this through two features: Iris high-def, AI-enhanced imaging and Elekta ONE Online integrated into the linac.
 
The Iris feature lets clinicians visualize target areas with greater clarity, the company said. Elekta ONE Online brings distributed treatment planning, faster dose calculation and AI-driven automation for contouring and dose planning.
 
“With Evo, we are making personalized, clinically effective adaptive radiation therapy treatments available to more patients,” said Elekta CEO Gustaf Salford. “We have seen great interest in Evo from our customers and we will start installing in the coming quarters.”